BIOA

Rating neutralAI Memo

BioAge Labs

As of 2026-10-17/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

QUELL-CV Phase 2 topline data • 2026-12-31

Base target: $5 / p=35% prob

Biggest risk

Biomarker improvement may not translate into patient benefit. QUELL-DME results are not expected until the second half of 2027, and clinical spending is rising: second-quarter R&D expense increased to $24.4 million from $19.8 million a year earlier. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm

Invalidation

Break below $2 or thesis failure.

What would change my mind?

BioAge reported $381.3 million of cash, cash equivalents and marketable securities at June 30, 2026 and estimated funding through 2029. Successful QUELL-CV data could strengthen the case for BGE-102 while QUELL-DME offers a later clinical-outcome test. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-17

Base target

p=35%

Bull target

p=20%

Bear target

p=45%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

QUELL-DME Phase 2 topline data
BioAge reported $381.3 million of cash, cash equivalents and marketable securities at June 30, 2026 and estimated funding through 2029.
Successful QUELL-CV data could strengthen the case for BGE-102 while QUELL-DME offers a later clinical-outcome test.

BearKey bullets

Higher BGE-102 trial spending may erode the June 30 cash balance despite management's then-current runway estimate.
[#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm
Low coverage and loose peer comparability make target prices and event-reaction estimates especially uncertain.

WatchKey bullets

QUELL-CV Phase 2 topline data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $5 (p=35%)

Target spread vs base: +88% / -58%

Scenario probabilities

Bull Target: $9 (p=20%)Base Target: $5 (p=35%)Bear Target: $2 (p=45%)

Commentary

The October 2 filing adds a defined QUELL-DME Phase 2 design and second-half 2027 timing, but does not resolve efficacy. The supplied price anchor is $4.84 on October 16. A verified post-filing price-reaction explanation and current analyst revisions are unavailable. The zero-valued sentiment fields denote unavailable measurements, not neutral readings. The deterministic prior is negative; low coverage favors monitoring rather than a bullish inference. [#8-K-2026-10-02] https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm

As of 2026-10-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

QUELL-DME Phase 2 topline data

Scenarios

Bull Target (Scenario probability)

$9 / p=20% prob

Base Target (Scenario probability)

$5 / p=35% prob

Bear Target (Scenario probability)

$2 / p=45% prob

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
QUELL-CV Phase 2 topline data
BioAge expects BGE-102 data in the second half of 2026. The primary endpoint is change in hsCRP, a biomarker; a favorable result would support dose selection but would not establish clinical benefit. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm
Prob 45.00% • Move 30.00% • Priced-in 35.00%
EVENT2026-12-31
First APJ-program IND filing
BioAge stated that it intends to file its first investigational new drug application for an APJ program by year-end 2026. Filing would mark development progress, not efficacy. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm
Prob 60.00% • Move 8.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

QUELL-DME Phase 2 topline data
2027-12-31
The October 2 filing confirms first dosing in an approximately 180-participant trial and anticipates results in the second half of 2027. Its visual-acuity endpoint tests a clinical outcome; the trial remains early proof of concept. [#8-K-2026-10-02] https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm
Prob 35% • Move 30% • Priced-in 20%

Risks

Higher BGE-102 trial spending may erode the June 30 cash balance despite management's then-current runway estimate. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm
Low coverage and loose peer comparability make target prices and event-reaction estimates especially uncertain.
QUELL-CV's hsCRP endpoint is a pharmacodynamic biomarker, not proof of cardiovascular benefit.
QUELL-DME faces clinical efficacy, safety and enrollment risk; its anticipated second-half 2027 readout is distant. [#8-K-2026-10-02] https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm

Peers

Symbol	Summary
LXEO	Similarly sized biotech candidate; different therapeutic focus limits valuation comparability.
BBOT	Similarly sized clinical-stage biotech candidate, but oncology focus makes it a loose event-risk comparison rather than a direct BGE-102 valuation peer.
QTTB	Similarly sized biotech candidate, but the packet does not establish comparable indication, modality, or clinical stage.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-17

Loading AI feed…

Symbol

Summary

LXEO

Similarly sized biotech candidate; different therapeutic focus limits valuation comparability.

BBOT

Similarly sized clinical-stage biotech candidate, but oncology focus makes it a loose event-risk comparison rather than a direct BGE-102 valuation peer.

QTTB

Similarly sized biotech candidate, but the packet does not establish comparable indication, modality, or clinical stage.